Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0WK0P
|
||||
| Former ID |
DIB009011
|
||||
| Drug Name |
Topiroxostat
|
||||
| Synonyms |
FYX-051; Xanthine oxidoreductase inhibitor (oral, gout), Fuji Yakuhin
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Gout [ICD9: 274.00274.1274.8274.9; ICD10:M10] | Phase 2 | [1] | ||
| Company |
Fuji Yakuhin Kogyo Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H8N6
|
||||
| Canonical SMILES |
c1(cc(ccn1)c1n[nH]c(n1)c1ccncc1)C#N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Xanthine dehydrogenase/oxidase | Target Info | Inhibitor | [2] | |
| BioCyc Pathway | Purine nucleotides degradation | ||||
| Urate biosynthesis/inosine 5'-phosphate degradation | |||||
| Guanosine nucleotides degradation | |||||
| Adenosine nucleotides degradation | |||||
| Retinoate biosynthesis II | |||||
| KEGG Pathway | Purine metabolism | ||||
| Caffeine metabolism | |||||
| Drug metabolism - other enzymes | |||||
| Metabolic pathways | |||||
| Peroxisome | |||||
| PANTHER Pathway | Adenine and hypoxanthine salvage pathway | ||||
| Purine metabolism | |||||
| PathWhiz Pathway | Caffeine Metabolism | ||||
| Purine Metabolism | |||||
| Reactome | Purine catabolism | ||||
| WikiPathways | Oxidative Stress | ||||
| Effects of Nitric Oxide | |||||
| Metabolism of nucleotides | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02327754) Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout. U.S. National Institutes of Health. | ||||
| REF 2 | QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.